Treatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan-effects on oxidized non-esterified free fatty acids and cytokine production

Cardiovascular Drugs and Therapy

Volumn 23, Issue 4, 2009, Pages 289-294

  Rosenson, Robert S ^a  

^a Downstate Health Sciences University   (United States)

Author keywords

Angiotensin receptor antagonists; Calcium channel blockers; Hypertension; Oxidative stress

Indexed keywords

AMLODIPINE; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FATTY ACID; HYDROCHLOROTHIAZIDE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; OLMESARTAN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADD ON THERAPY; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIAC PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; HYPERTENSION; MALE; METABOLIC SYNDROME X; OXIDATIVE STRESS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; CELL ADHESION MOLECULES; CYTOKINES; DOUBLE-BLIND METHOD; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; LIPOPOLYSACCHARIDES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; TETRAZOLES;

EID: 69249205426     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-009-6185-4     Document Type: Article

References (14)

1. L Dalla Libera B Ravara A Angelini K Rossini M Sandri G Thiene, et al. 2001 Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure Circulation 103 2195 200
2. GW De Keulenaer RW Alexander M Ushio-Fukai N Ishizaka KK Griendling 1998 Tumour necrosis factor alpha activates a p22phox-based nadh oxidase in vascular smooth muscle Biochem J 329 653 7
3. SM Grundy JI Cleeman SR Daniels KA Donato RH Eckel BA Franklin, et al. 2005 Diagnosis and management of the metabolic syndrome: An American Heart Association/national heart, lung, and blood institute scientific statement Circulation 112 2735 52
4. J Kaikkonen TP Tuomainen K Nyyssonen JD Morrow JT Salonen 2004 C18 hydroxy fatty acids as markers of lipid peroxidation ex vivo and in vivo Scand J Clin Lab Invest 64 457 68
5. Chan H. Autoxidation of unsaturated lipids. London: Academic; 1987.
6. RS Rosenson CC Tangney DM Levine TS Parker BR Gordon 2005 Association between reduced low density lipoprotein oxidation and inhibition of monocyte chemoattractant protein-1 production in statin-treated subjects J Lab Clin Med 145 83 7
7. T Hayek J Attias R Coleman S Brodsky J Smith JL Breslow, et al. 1999 The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein e deficient mice Cardiovasc Res 44 579 87
8. MA Hernandez-Presa C Bustos M Ortego J Tunon L Ortega J Egido 1998 Ace inhibitor quinapril reduces the arterial expression of nf-{kappa}b-dependent proinflammatory factors but not of collagen i in a rabbit model of atherosclerosis Am J Pathol 153 1825 37
9. M Miyazaki H Sakonjo S Takai 1999 Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in cynomolgus monkeys fed a high-cholesterol diet Br J Pharmacol 128 523 9
10. S Hope P Brecher AV Chobanian 1999 Comparison of the effects of at1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis[ast] Am J Hypertens 12 28 34
11. WB Strawn MC Chappell RH Dean S Kivlighn CM Ferrario 2000 Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia Circulation 101 1586 93
12. H Yoshida M Avaori M Suzukawa H Hosoai M Nishiwaki T Ishikawa, et al. 1995 Effects of ca-antagonists on oxidative susceptibility of low density lipoprotein (LDL) Hypertens Res 18 47 53
13. G Sobal EJ Menzel H Sinzinger 2001 Calcium antagonists as inhibitors ofin vitro low density lipoprotein oxidation and glycation Biochem Pharmacol 61 373 9
14. H Toba T Shimizu S Miki R Inoue A Yoshimura R Tsukamoto, et al. 2006 Calcium channel blockers reduce angiotensin II-induced superoxide generation and inhibit lectin-like oxidized low-density lipoprotein receptor-1 expression in endothelial cells Hypertens Res 29 105 16